0

Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graff?

The market access process in the Netherlands can be very special, especially for medical devices. Besides standard reimbursement processes with evidence-based medicine assessments, there are also more pragmatic pathways available. How do these work and what needs to be considered… Continue Reading

0

The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?

Belgium has created a similar fast-track process as in Germany even though that some differences exist. Anyway, core question with new processes is always how the rules are being interpreted and applied. So, how important are clinical studies and when… Continue Reading

0

The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?

The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow, access and commercialization, especially of new and innovative therapies could firstly be introduced through the private system.… Continue Reading